Richard Gonzalez, AbbVie CEO (AP Photo/Pablo Martinez Monsivais)
January 6, 2024 09:16 AM EST
Deals

Cerev­el failed to draw Pfiz­er in­to a bid­ding war, but got Ab­b­Vie to up its price any­way, fil­ing shows

Kyle LaHucik

Senior Reporter

Ab­b­Vie’s $45-per-share, $8.7 bil­lion ac­qui­si­tion of the neu­ro­science drug de­vel­op­er Cerev­el Ther­a­peu­tics was $10 per share high­er than its ini­tial bid, ac­cord­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

No­vo Nordisk to phase out its pro­duc­tion of hu­man in­sulin pens glob­al­ly

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times